X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with WYETH LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs WYETH LTD - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES WYETH LTD DIVIS LABORATORIES/
WYETH LTD
 
P/E (TTM) x 30.0 27.7 108.2% View Chart
P/BV x 5.2 5.3 97.2% View Chart
Dividend Yield % 1.0 1.3 74.8%  

Financials

 DIVIS LABORATORIES   WYETH LTD
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
WYETH LTD
Mar-13
DIVIS LABORATORIES/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs1,2221,044 117.0%   
Low Rs784818 95.8%   
Sales per share (Unadj.) Rs153.1298.6 51.3%  
Earnings per share (Unadj.) Rs39.957.2 69.8%  
Cash flow per share (Unadj.) Rs44.658.4 76.3%  
Dividends per share (Unadj.) Rs10.0017.00 58.8%  
Dividend yield (eoy) %1.01.8 54.6%  
Book value per share (Unadj.) Rs201.8249.5 80.9%  
Shares outstanding (eoy) m265.4722.72 1,168.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.63.1 210.0%   
Avg P/E ratio x25.116.3 154.3%  
P/CF ratio (eoy) x22.515.9 141.1%  
Price / Book Value ratio x5.03.7 133.2%  
Dividend payout %25.029.7 84.3%   
Avg Mkt Cap Rs m266,26621,157 1,258.5%   
No. of employees `0009.70.5 1,978.7%   
Total wages/salary Rs m4,687400 1,171.9%   
Avg. sales/employee Rs Th4,175.013,787.4 30.3%   
Avg. wages/employee Rs Th481.5813.0 59.2%   
Avg. net profit/employee Rs Th1,089.32,643.3 41.2%   
INCOME DATA
Net Sales Rs m40,6436,783 599.2%  
Other income Rs m749353 212.4%   
Total revenues Rs m41,3927,136 580.0%   
Gross profit Rs m14,4601,617 894.1%  
Depreciation Rs m1,23327 4,636.5%   
Interest Rs m236 410.9%   
Profit before tax Rs m13,9531,938 720.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m3,349632 529.8%   
Profit after tax Rs m10,6041,301 815.4%  
Gross profit margin %35.623.8 149.2%  
Effective tax rate %24.032.6 73.6%   
Net profit margin %26.119.2 136.1%  
BALANCE SHEET DATA
Current assets Rs m40,1056,984 574.3%   
Current liabilities Rs m6,5952,056 320.8%   
Net working cap to sales %82.572.6 113.5%  
Current ratio x6.13.4 179.0%  
Inventory Days Days11999 119.4%  
Debtors Days Days8124 337.0%  
Net fixed assets Rs m19,995244 8,184.6%   
Share capital Rs m531227 233.7%   
"Free" reserves Rs m53,0435,441 974.9%   
Net worth Rs m53,5745,668 945.2%   
Long term debt Rs m025 0.0%   
Total assets Rs m61,5857,901 779.5%  
Interest coverage x618.4353.3 175.0%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.70.9 76.9%   
Return on assets %17.316.5 104.4%  
Return on equity %19.822.9 86.3%  
Return on capital %26.134.0 76.6%  
Exports to sales %00.2 0.0%   
Imports to sales %25.236.3 69.5%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs m10,2592,465 416.1%   
Fx inflow Rs m35,38415 232,788.5%   
Fx outflow Rs m10,3992,677 388.4%   
Net fx Rs m24,985-2,662 -938.6%   
CASH FLOW
From Operations Rs m11,493923 1,244.9%  
From Investments Rs m-11,372317 -3,588.4%  
From Financial Activity Rs m-93-481 19.4%  
Net Cashflow Rs m28759 3.7%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 11.8 11.3 104.4%  
FIIs % 19.0 7.2 263.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 30.4 56.6%  
Shareholders   31,796 21,978 144.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   J.B.CHEMICALS  SUVEN LIFE  STERLING BIOTECH  CADILA HEALTHCARE  VENUS REMEDIES  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Firm US Markets; Sun Pharma, Software Stocks & Other Top Cues to Sway the Markets Today(Pre-Open)

Indian share markets finished the previous trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Blueprint for Sensex 100,000(The 5 Minute Wrapup)

Feb 20, 2018

Investing in stocks is not about index gazing. There are 3-Ms that could help pick the right stocks.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

A New Quest for the Stock Market's MOST Profitable Ideas...(Smart Contrarian)

Feb 23, 2018

If you want to receive the best ideas in the Indian stick markets...you need to heed this important announcement.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 26, 2018 09:33 AM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS